- Home
- USCB vs OLMA Comparison
USCB vs OLMA Comparison
Compare USCB & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- OLMA
- Stock Information
- Founded
- USCB 2002
- OLMA 2006
- Country
- USCB United States
- OLMA United States
- Employees
- USCB N/A
- OLMA N/A
- Industry
- USCB Major Banks
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- USCB Finance
- OLMA Health Care
- Exchange
- USCB Nasdaq
- OLMA Nasdaq
- Market Cap
- USCB 316.4M
- OLMA 378.9M
- IPO Year
- USCB 2021
- OLMA 2020
- Fundamental
- Price
- USCB $17.34
- OLMA $5.46
- Analyst Decision
- USCB Buy
- OLMA Strong Buy
- Analyst Count
- USCB 3
- OLMA 5
- Target Price
- USCB $20.33
- OLMA $24.00
- AVG Volume (30 Days)
- USCB 16.8K
- OLMA 450.7K
- Earning Date
- USCB 07-24-2025
- OLMA 08-11-2025
- Dividend Yield
- USCB 2.30%
- OLMA N/A
- EPS Growth
- USCB 67.08
- OLMA N/A
- EPS
- USCB 1.47
- OLMA N/A
- Revenue
- USCB $88,094,000.00
- OLMA N/A
- Revenue This Year
- USCB $26.38
- OLMA N/A
- Revenue Next Year
- USCB $4.39
- OLMA N/A
- P/E Ratio
- USCB $11.83
- OLMA N/A
- Revenue Growth
- USCB 32.06
- OLMA N/A
- 52 Week Low
- USCB $13.85
- OLMA $2.86
- 52 Week High
- USCB $21.86
- OLMA $13.93
- Technical
- Relative Strength Index (RSI)
- USCB 55.15
- OLMA 54.42
- Support Level
- USCB $17.10
- OLMA $5.54
- Resistance Level
- USCB $17.98
- OLMA $5.85
- Average True Range (ATR)
- USCB 0.52
- OLMA 0.30
- MACD
- USCB 0.06
- OLMA -0.01
- Stochastic Oscillator
- USCB 73.38
- OLMA 51.79
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.